Antigenics (AGEN) Posts Q3 Loss of $0.13, Revs Up Y/Y
More News related to AGEN
- Antigenics (AGEN) Kidney Cancer Treatment Oncophage Receives Negative Opinion from CHMP
- European CHMP Formally Adopts Negative Opinion on Oncophage(R)
- Antigentics (AGEN) Announces 8.5M Common Shelf
- Antigenics (AGEN) Indicated that Glaxo's malaria Vaccine Phase III Enrolled 5000 Children to Date
- Antigenics Provides Details On GlaxoSmithKline's Pivotal Malaria Vaccine Trial With QS-21 Adjuvant
More News related to Earnings
- Peet's (PEET) Moving Even Lower as Cowen Issues Mid-Day Downgrade
- RBC Downgrades Cephalon (CEPH) Following Cinquil Trial Results; Sees 'Little Momentum' Behind the Stock
- BMO Capital Downgrades Terra Industries (TRA) to Market Perform
- FTN Equity Downgrades Momenta Pharmaceuticals (MNTA) to Neutral
- Sterne Agee Downgrades Shoe Apparel Stores FINL & FL
Antigenics Inc. (NASDAQ: AGEN) reports Q3 loss of $0.13, compared to ($0.17) in the same quarter last year. Revenue for the quarter was $896 million, versus $685 million in Q308.
Related Categories
EarningsStocks Mentioned
-0.14Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
